| Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders (NCT05803616) | University Hospital, Geneva | 2022-05-23 |
| Trial of Written Exposure for Metastatic Cancer Patients (EASE) (NCT06042400) | University of Colorado, Boulder | 2022-04-18 |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples (NCT05001386) | Hospices Civils de Lyon | 2022-03-01 |
| Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma (NCT05155215) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2021-12-31 |
| Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) (NCT07445984) | Azienda Ospedaliero-Universitaria di Parma | 2021-07-28 |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (NCT04554914) | Pierre Fabre Medicament | 2021-07-14 |
| Expression of CD19 Complex in Lymphoproliferative Disorders (NCT04734470) | Assiut University | 2021-03-01 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity (NCT04339777) | National Cancer Institute (NCI) | 2020-09-22 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084) | Celularity Incorporated | 2020-05-12 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders (NCT03601819) | University of Michigan Rogel Cancer Center | 2019-05-15 |
| Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724) | National Cancer Institute (NCI) | 2019-04-18 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157) | UNC Lineberger Comprehensive Cancer Center | 2018-10-29 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (NCT03663933) | National Cancer Institute (NCI) | 2018-09-04 |
| Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies (NCT03397706) | Viracta Therapeutics, Inc. | 2018-03-29 |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy (NCT03394365) | Pierre Fabre Medicament | 2017-12-29 |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03373019) | Fudan University | 2017-12-21 |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (NCT02690545) | UNC Lineberger Comprehensive Cancer Center | 2016-08-26 |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (NCT02663297) | UNC Lineberger Comprehensive Cancer Center | 2016-06-07 |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (NCT02973113) | Baylor College of Medicine | 2016-02-16 |
| Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (NCT02579967) | National Cancer Institute (NCI) | 2015-11-19 |
| Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients (NCT02505789) | St. Justine's Hospital | 2013-05-01 |
| Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders (NCT00968461) | M.D. Anderson Cancer Center | 2013-05-01 |
| Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) (NCT01186224) | University of Liverpool | 2010-05-01 |
| Pathogenesis of Hematologic Malignancies (NCT01728402) | OHSU Knight Cancer Institute | 2008-09-01 |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) (NCT00579111) | Baylor College of Medicine | 2007-06-01 |
| Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies (NCT00131014) | Dana-Farber Cancer Institute | 2004-08-09 |
| Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease (NCT00123942) | MedImmune LLC | 2004-04-01 |
| Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma (NCT00068146) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-09-19 |
| Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant (NCT00063648) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2002-05-01 |
| Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). (NCT00058604) | Baylor College of Medicine | 2001-01-01 |
| Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H (NCT00048412) | Baylor College of Medicine | 2000-06-01 |
| Clofarabine in Chronic Lymphocytic Leukemia (NCT00028418) | M.D. Anderson Cancer Center | 1999-02-01 |
| A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes (NCT00001438) | National Cancer Institute (NCI) | 1995-06-01 |
| Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies (NCT02822495) | Atara Biotherapeutics | |
| Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders (NCT00002153) | DEKK-TEC, Inc. | |